Abstract:Background: Pancreatic cancer is a leading cause of cancer-related death in the world. With a feature of aggressive behaviours, pancreatic cancer showed early metastasis and quickly recurrence from surgery. Arginine deiminase (ADI) has been shown that it can inhibit the growth of some tumor cells deficient in argininosuccinate synthetase by arginine deprivation. However, whether the agent can inhibit pancreatic cancer cell invasion is not clear. Methods: Human pancreatic cancer cells BxPc-3 and PANC-1 were cultured. Scratch test and Transwell chamber invasion assay were used to examine the migration and invasion of BxPc-3 and PANC-1 cells treated with ADI. Also, the levels of molecular changes in ADI-treated pancreatic cancer cell were measured by Western blotting and real-time quantitative polymerase chain reaction (qPCR). Results: Treatment with ADI decreased the migration and invasion of PANC-1 cells deficient in argininosuccinate synthetase (ASS) in a dose- and time-dependent manner (from 0.5 mU to 5 mU), but not BxPC-3 pancreatic cancer cell expressed high level of ASS. In mRNA analysis, ADI (1 mU) down-regulated the levels of MMP-2, MMP-9, and uPA in PANC-1 cell, while up-regulated TIMP-2 and E-Cadherin level. Further protein expression analysis showed that ADI (1 mU) modulated the expression of MMP2, uPA, and E-Cadherin similar to mRNA detection. For getting the molecular mechanism of PANC-1 cells invasion inhibition by ADI treatment, we analyzed PI3KCA expression, and phosphorylation levels of p65, AKT and ERK1/2 in PANC-1 cells treated by ADI (1 mU) in combination with or without PI3K inhibitor LY294002 (20 µM), and the findings showed ADI reduced the expression levels of p-p65 (Ser536) and p-AKT (Thr308), which can be enhanced by addition of LY294002. However, ADI (1 mU) did not downregulate ERK1/2 phosphorylation at Thr202/Tyr204, as compared with control. Conclusion: Our results suggest that arginine deprivation by ADI can inhibit argininosuccinate synthetase-deficient PANC-1 cell invasion via suppression of PI3K/AKT/NF-&kgr;B signal.

Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase

Arginine-Depleting Enzymes – An Increasingly Recognized Treatment Strategy for Therapy-Refractory Malignancies

Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment

Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy

Investigation of fermentation process of arginine deiminase in Enterococcus faecalis

Arginine deprivation as a strategy for cancer therapy: An insight into drug design and drug combination

Arginine Signaling and Cancer Metabolism

Study on the new target of the individual treatment of breast cancer by argininosuccinate synthetase 1

Enhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum

Recombinant Arginine Deiminase from Levilactobacillus brevis Inhibits the Growth of Stomach Cancer Cells, Possibly by Activating the Intrinsic Apoptosis Pathway

Targeting arginine metabolism pathway to treat arginine-dependent cancers.

Arginine Deiminase Inhibit Argininosuccinate Synthetase-Deficient PANC-1 Cell Invasion Via Suppression of Pi3K/Akt/Nf-κB Signal

Arginine Deiminase Modulates Endothelial Tip Cells Via Excessive Synthesis of Reactive Oxygen Species.

An Engineered Arginase FC Protein Inhibits Tumor Growth in Vitro and in Vivo.

Arginine Metabolism and Its Potential in Treatment of Colorectal Cancer

Arginine deiminase produced by lactic acid bacteria as a potent anti-cancer drug

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

Deciphering molecular mechanisms of arginine deiminase-based therapy - Comparative response analysis in paired human primary and recurrent glioblastomas

Arginine deprivation/citrulline augmentation with ADI-PEG20 as novel therapy for complications in type 2 diabetes

Enhanced anti-tumor activity of arginine decarboxylase through the incorporation of aromatic amino acids at the multimer-forming interface

Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression